Suppression of P-glycoprotein expression by antipsychotics trifluoperazine in adriamycin-resistant L1210 mouse leukemia cells

European Journal of Pharmaceutical Sciences

Volumn 28, Issue 4, 2006, Pages 300-306

  Shin, Soon Young ^a   Choi, Byeong Hyeok ^a   Kim, Jae Ryong ^b   Kim, Jung Hye ^b   Lee, Young Han ^a  

^a Department of Bio Nano Technology   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

Author keywords

Multidrug resistance; P glycoprotein; Trifluoperazine

Indexed keywords

DOXORUBICIN; GENE PRODUCT; GLYCOPROTEIN P; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; TRIFLUOPERAZINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; GENE OVEREXPRESSION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION TERMINATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIPSYCHOTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; LEUKEMIA; MICE; NF-KAPPA B; NIH 3T3 CELLS; P-GLYCOPROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TRIFLUOPERAZINE;

EID: 33646840483     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.03.002     Document Type: Article

References (33)

1. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., and Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 22 (2003) 7468-7485
2. Bhat U.G., Winter M.A., Pearce H.L., and Beck W.T. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Mol. Pharmacol. 48 (1995) 682-689
3. Bruera E., and Nemann C.M. The uses of psychotropics in symptom management in advanced cancer. Psychology 7 (1998) 346-358
4. Cohen D., Piekarz R.L., Hsu S.I., DePinho R.A., Carrasco N., and Horwitz S.B. Structural and functional analysis of the mouse mdr1b gene promoter. J. Biol. Chem. 266 (1991) 2239-2244
5. Fardel O., Lecureur V., and Guillouzo A. The P-glycoprotein multidrug transporter. Gen. Pharmacol. 27 (1996) 1283-1291
6. Ford J.M., Prozialeck W.C., and Hait W.N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol. 35 (1989) 105-115
7. Furuya K.N., Thottassery J.V., Schuetz E.G., Sharif M., and Schuetz J.D. Bromocriptine transcriptionally activates the multidrug resistance gene (pgp2/mdr1b) by a novel pathway. J. Biol. Chem. 272 (1997) 11518-11525
8. Ganapathi R., Kuo T., Teeter L., Grabowski D., and Ford J. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells. Mol. Pharmacol. 39 (1991) 1-8
9. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev. Cancer (Phila.) 2 (2002) 48-58
10. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62 (1993) 385-427
11. Grant C.E., Valdimarsson G., Hipfner D.R., Almquist K.C., Cole S.P., and Deeley R.G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54 (1994) 357-361
12. Grilli M., Chiu J.J., and Leonardo M.J. NF-kappa B and Rel: participants in a multiform transcriptional regulatory system. Int. Rev. Cytol. 143 (1993) 1-62
13. Hendrich A.B., Wesolowska O., and Michalak K. Trifluoperazine induces domain formation in zwitterionic phosphatidylcholine but not in charged phosphatidylglycerol bilayers. Biochim. Biophys. Acta 1510 (2001) 414-425
14. Kaufmann S.H., Desnoyers S., Ottaviano Y., Davidson N.E., and Poirier G.G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53 (1993) 3976-3985
15. Kim J.R., and Kim J.H. A vincristine-resistant L1210 subline shows cross-resistance, mdr gene amplification and Overexpression. Korean J. Biochem. 26 (1994) 67-76
16. Kim S.Y. Expression of multidrug resistance-associated protein (MRP), c-myc and c-fos in L1210 cells. Yeungnam Univ. Med. J. 14 (1997) 67-76
17. Kim S.Y., Son S.K., Kim J.R., and Kim J.H. Membrane protein alterations associated with anticancer drug resistance in mouse lymphoblastic leukemia L1210 cells. Yeungnam Univ. Med. J. 10 (1993) 432-444
18. Lahti R.A., Evans D.L., Stratman N.C., and Figur L.M. Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur. J. Pharmacol. 236 (1993) 483-486
19. Miller R.L., Bukowski R.M., Budd G.T., Purvis J., Weick J.K., Shepard K., Midha K.K., and Ganapathi R. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J. Clin. Oncol. 6 (1988) 880-888
20. Naftalovich S., Yefenof E., and Eilam Y. Antitumor effects of ketoconazole and trifluoperazine in murine T-cell lymphomas. Cancer Chemother. Pharmacol. 28 (1991) 384-390
21. Nordenberg J., Fenig E., Landau M., Weizman R., and Weizman A. Effects of psychotropic drugs on cell proliferation and differentiation. Biochem. Pharmacol. 58 (1999) 1229-1236
22. Osborn M., and Weber K. Damage of cellular functions by trifluoperazine, a calmodulin-specific drug. Exp. Cell. Res. 130 (1980) 484-488
23. Rayet B., and Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18 (1999) 6938-6947
24. Riordan J.R., Dechars K., Kartner N., Alon N., Trent J., and Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316 (1985) 817-819
25. Shah G.M., Shah R.G., and Poirier G.G. Different cleavage pattern for poly(ADP-ribose) polymerase during necrosis and apoptosis in HL-60 cells. Biochem. Biophys. Res. Commun. 229 (1996) 838-844
26. Shin S.Y., Kim C.G., Hong D.D., Kim J.H., and Lee Y.H. Implication of Egr-1 in trifluoperazine-induced growth inhibition in human U87MG glioma cells. Exp. Mol. Med. 36 (2004) 380-386
27. Shin S.Y., Kim C.G., Ko J., Min D.S., Chang J.S., Ohba M., Kuroki T., Choi Y.B., Kim Y.H., Na D.S., Kim J.W., and Lee Y.H. Transcriptional and post-transcriptional regulation of the PKCδ gene by etoposide in L1210 murine leukemia cells: implication of PKCδ autoregulation. J. Mol. Biol. 340 (2004) 681-693
28. Simon S.M., and Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. USA 91 (1994) 3497-3504
29. Sonneveld P., and Wiemer E. Inhibitors of multidrug resistance. Curr. Opin. Oncol. 9 (1997) 543-548
30. Takano H., Fukushi H., Morishima Y., and Shirasaki Y. Calmodulin and calmodulin-dependent kinase II mediate neuronal cell death induced by depolarization. Brain Res. 962 (2003) 41-47
31. Tewari M., Quan L.T., O'Rourke K., Desnoyers S., Zeng Z., Beidler D.R., Poirier G.G., Salvesen G.S., and Dixit V.M. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81 (1995) 801-809
32. Zhou G., and Kuo M.T. NF-κB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J. Biol. Chem. 272 (1997) 15174-15183
33. Zhou G., Song R., and Kuo M.T. A novel cis-acting element is involved in the promoter activity of the rat mdr1b gene. Cell Growth Differ. 7 (1996) 1369-1381